USC Researchers Identify Potential Alzheimer’s Treatment Targeting Brain Inflammation

Researchers at the University of Southern California have identified a promising new therapeutic pathway for Alzheimer’s disease by targeting an enzyme linked to neuroinflammation. The study, published in npj Drug Discovery, focuses on calcium-dependent phospholipase A2 (cPLA2), an enzyme that appears to be overactive in individuals carrying the APOE4 gene—the most significant genetic risk factor for Alzheimer’s. By modulating this enzyme, scientists hope to mitigate the inflammatory processes that contribute to cognitive decline.

A primary challenge in this research was the dual nature of cPLA2; while it fuels harmful inflammation in the context of Alzheimer’s, it is also essential for maintaining healthy brain function. To address this, the USC team utilized advanced computational screening to evaluate billions of molecules, identifying compounds capable of selectively inhibiting the enzyme’s pathological activity without disrupting its necessary biological roles. Furthermore, these compounds were specifically engineered to cross the blood-brain barrier, a critical requirement for effective neurological treatment.

Early results from cell-based and animal models have been encouraging, showing that the lead candidate compound successfully reaches the brain and reduces neuroinflammatory pathways. This discovery represents a significant step forward in personalized medicine, particularly for APOE4 carriers who are at a higher risk for the disease. The research team is now shifting its focus toward rigorous safety and feasibility testing to determine if this targeted approach can effectively alter the trajectory of Alzheimer’s in human patients.

This development is significant because it moves beyond generalized treatments, offering a more precise mechanism to address the specific inflammatory triggers associated with genetic predisposition. By successfully isolating the harmful activity of cPLA2, the researchers have opened a new door for potential drug development that could eventually slow or prevent the progression of neurodegenerative disorders.